Institut Pasteur Korea(IPK) announced a study result that the COVID-19 drug and drug candidates exhibited equally effective antiviral efficacy against the SARS-CoV-2 variants from the UK and South Africa as against the early virus in its cell experiments. Among the drugs analyzed in this study, nafamostat is a strong COVID-19 drug candidate currently undergoing domestic and overseas clinical trials in cooperation with CKD Pharma as its potent antiviral efficacy was confirmed by IPK last year which the research institute confirmed last year. On April 15, the Ministry of Food and Drug Safety approved CKD Pharma's Nafabelltan (main ingredient: nafamostat), for Phase 3 clinical trial. 

Dong-A Ilbo (Apr. 16, 2021)

Approval of Phase 3 Clinical Trials Granted for the Nafabellan, a COVID-19 candidate of CKD Pharma... Promoting Multinational Clinical Trials Targeting 600 Patients

Go to the article >>